Adicet Bio, Inc.

NASDAQ:ACET

Biotechnology

Healthcare
$5.53 +0.25%

+$0.02 today

Market cap
$51.70M
Beta
1.57
P/E (TTM)
-0.8
EPS (TTM)
-$10.13
52W Low $6.01High $17.44

Volume 0.15M

Average 0.12M

ACET Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Adicet Bio, Inc.NASDAQ: ACET

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $1.33M fell 20.6% year over year, ahead of the -46.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -20.6% holds above the trailing-twelve-month pace of -46.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.33M-3.2% QoQ
Last fiscal yearDec 2025
$5.31M-49.4% YoY
LTMMar 2026
$4.97M-46.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.6%——
1 year-49.4%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
5.31M USD
Year-over-year change
-49.4%

Other Income / Expenses vs competitors

How ACET compares with its peers on the latest reported figures

  • ACET's LTM Mar 2026 other income / expenses of $4.97M is the 3rd highest of the 8 companies compared; the peer median is $4.4M.
  • Its year-over-year change of -46.6% is the 5th highest of 7, against a peer median of -46.3%.
  • Over three fiscal years its annual growth of +24.4% compares with a peer median of +60.9%.
ACET Competitors Peer median
Other Income / Expenses for ACET and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMUXImmunic, Inc.LTM Mar 2026$5.35M +16.3%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.09M -46.1%+60.9%—
ACETAdicet Bio, Inc.LTM Mar 2026$4.97M -46.6%+24.4%—
ADAGAdagene Inc.LTM Jun 2024$4.52M —-7.1%554.5%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$4.4M -46.5%+144.2%48.1%
GANXGain Therapeutics, Inc.LTM Mar 2026-$601.23K -1940.7%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$7.35M -12.1%—320.6%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-$9.04M -6403.6%—43.0%
Peer median (excluding ACET) $4.4M-46.3%+60.9%184.4%

Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.73M24.99M000
Cost of Revenue00006.38M
Gross Profit9.73M24.99M00(6.38M)
Gross Margin100.0%100.0%———
Research & Development48.94M71.25M106.04M99.32M99.13M
Selling, General & Admin22.22M26.3M26.53M28.29M22.99M
Operating Expenses71.16M97.54M152.04M127.62M115.73M
Depreciation & Amortization1.54M5.01M6.1M6.47M6.38M
EBITDA(60.41M)(64.7M)(136.54M)(110.65M)(110.39M)
EBITDA Margin-620.9%-258.9%———
Operating Income(61.43M)(72.55M)(152.04M)(127.62M)(122.11M)
Operating Margin-631.4%-290.3%———
Interest Income91K3.76M9.98M10.71M5.78M
Interest Expense176K80K25K4K36K
Other Income / Expenses(691K)2.76M9.38M10.49M5.31M
Income Before Tax(62.12M)(69.79M)(142.66M)(117.12M)(116.8M)
Pre-Tax Margin-638.5%-279.3%———
Income Tax Expense(125K)0000
Net Income(62M)(69.79M)(142.66M)(117.12M)(116.8M)
Net Margin-637.2%-279.3%———
EPS (Basic)(32.00)(27.20)(52.96)(21.28)(16.95)
EPS (Diluted)(32.00)(27.20)(52.96)(21.28)(16.95)
Weighted Avg Shares1.93M2.57M2.69M5.49M6.89M
Weighted Avg Shares (Diluted)1.93M2.57M2.69M5.49M6.89M

Adicet Bio, Inc.

NASDAQ:ACET

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.